LINK ALTERNATIF MBL77 - AN OVERVIEW

Not all people with CLL demand therapy. Regardless of all recent innovations, the iwCLL continue to recommends watchful observation for sufferers with asymptomatic condition.86 This recommendation is based on at least two randomized trials evaluating observation to both chlorambucil monotherapy or fludarabine, cyclophosphamide and rituximab (FCR).1